Viagenpumatucel-L

BIOLOGICAL2 trials

Sponsors

Heat Biologics

Conditions

Non Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

CompletedNCT02439450

Heat BiologicsNon-small Cell Lung Cancer

Start: 2015-04-15End: 2022-11-04Updated: 2023-09-21

Phase 2

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

TerminatedNCT02117024

Heat BiologicsNon Small Cell Lung Cancer

Start: 2014-07-31End: 2018-04-30Updated: 2020-02-05

Related Papers

Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.

Journal of Clinical Oncology2021-05-2010 citations

Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab.

Journal of Clinical Oncology2020-05-204 citations

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.

Journal of Clinical Oncology2019-05-205 citations

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-03-101 citations

Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.

Journal of Clinical Oncology2016-05-202 citations

First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial.

Journal of Clinical Oncology2015-05-201 citations